Drug Abuse Treatment Market to Surpass US$ 26.3 Bn Threshold by 2026 - Coherent Market Insights

Global Drug Abuse Treatment Market, by Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction), by Drug Type (Disulfiram, Acamprosate, Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment ((Nicotine Replacement Treatment (Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine Spray, and Nicotine Inhaler)) ((Non-Nicotine Medication, (Bupropion, and Varenicline)), and Others), by Distribution Channel (Hospital, Retail Pharmacy, and Online Pharmacy) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 13.4 Bn in 2017, and is projected to exhibit a CAGR of 7.8% over the forecast period (2018 – 2026). Increasing launches of novel drugs for treatment of drug abuse in market is expected to drive the global drug abuse treatment market growth in near future. For instance, in 2015, Mylan N.V. launched its new drugs Disulfiram Tablets USP, 250 mg and 500 mg in the U.S. market, drugs Disulfiram Tablets USP is a generic version of Odyssey Pharmaceutical's Antabuse. In 2017, Glenmark Pharmaceuticals launched its new nicotine replacement therapy namely Kwitz in India. Kwitz is a nicotine gum and is available in two variants Kwitz 2 mg and Kwitz 4 mg. Kwitz 2 mg is for the smokers having less than 20 cigarettes per day and Kwitz 4 mg is for those who smoke more than 20 cigarettes per day. In April 2018, Lil' Drug Store Products Inc. launched its Nicotac brand nicotine gum in market. Lil' Drug Store Products Inc. has launched its Nicotac in two nicotine strengths (2 mg and 4 mg nicotine polarcrilex). In 2017, Cipla Health, an arm of Cipla Limited launched a new Nicotex Nicotine Patches. Nicotex Nicotine Patches are skin/transdermal patches, which helps to quit smoking in 12 months. Company has launched its patches in 3 strengths 21 mg, 14 mg, and 7 mg. 21 mg patch is for one who smoke more than 20 cigarette a day, 14 mg is for those who smoke less that 20 cigarette a day

Browse 23 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on Drug Abuse Treatment Market By Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, and Opioid Addiction), By Drug Type (Disulfiram, Acamprosate, Naltrexone, Methadone, Buprenorphine, Nicotine Addiction Treatment ((Nicotine Replacement Treatment (Nicotine Patch, Nicotine Gum, Nicotine Lozenge, Nicotine Spray, Nicotine Inhaler)) ((Non-Nicotine Medication, (Bupropion, and Varenicline)), and Others), By Distribution Channel (Hospital, Retail Pharmacy, and Online Pharmacy)  and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

To know the latest trends and insights prevalent in the drug abuse treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/drug-abuse-treatment-market-2011

Furthermore, increasing prevalence of drug abuse and dependence in key regions are expected to increase the demand for its treatment and management drugs in near future. For instance, according to the Substance Abuse and Mental Health Services Administration (SAMHSA), around 830,000 people in the U.S. used heroin in 2015, which is more than double the number from 2002. Such increasing rates of drugs abuse are expected to fuel growth of the global drug abuse treatment market in near future.

Key Takeaways of the Drug Abuse Treatment Market:

• The global drug abuse treatment market is expected to exhibit a CAGR of 7.8% over the forecast period (2018 – 2026), owing to frequent product launches, approval and robust pipeline of novel biopharmaceutical products
• North America held the dominant position in the global drug abuse treatment market and is expected to retain its dominance over the forecast period (2018 – 2026). This is due to the high rates of drug abuse in region, which are expected to increase demand for its treatment drugs over the forecast period. For instance, according to the data published by National Institute of Alcohol abuse and Alcoholism in 2015, around 15.1 million adults ages 18 and older (6.2 percent of this age group) are suffering from Alcohol Use Disorder. This includes 9.8 million men (8.4 percent of men in this age group) and 5.3 million women
• Asia Pacific is expected to witness significant growth over the forecast period due to increasing launches of novel drugs by key players in the region. For instance, in 2017, Glenmark Pharmaceuticals launched a new Kwitz is a nicotine gum in India.
• Major players operating in the drug abuse treatment market include Cipla Limited, Glenmark Pharmaceuticals, Pfizer Inc., Mylan N.V., Odyssey Pharmaceuticals Inc., Lil' Drug Store Products Inc., Indivior Plc., Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., and British American Tobacco Plc.